📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-10-05 18:49
4 analysed today
FollowTelegram
4
Today
149,943
All-time analysed
42,986
Positive
6,669
Negative
91,580
Neutral
8,640
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
6 announcements match the current filters (relevance ≥ 5).
Deep Health AI to acquire ₹10.35 Cr debt of Sparion Infrastructure from Kshitij Polyline
Deep Health AI India Ltd's Board approved the acquisition of debt owed by Sparion Infrastructure Private Limited from Kshitij Polyline Limited for ₹10.35 Cr. The transaction will be executed via a Deed of Assignment on an 'as is where is' and 'without recourse' basis. The acquisition includes underlying security, specifically a pledge of 4,900 equity shares (49% stake) of Sparion Infrastructure. Relative to Deep Health AI's TTM revenue of ₹5 Cr and net worth of ₹52 Cr, this assignment represents a significant capital commitment of over 200% of annual revenue.
Confidence: HIGH
What changedDeep Health AI agreed to acquire ₹10.35 Cr worth of third-party corporate debt along with a 49% share pledge as security.
Why it mattersThe deal size of ₹10.35 Cr is massive compared to the company's TTM revenue of ₹5 Cr and market cap of ₹28 Cr, exposing the balance sheet to recovery risk on an unrated borrower.
Assignment consideration: ₹10,35,35,520/-Pledged stake in borrower: 49%Pledged shares count: 4,900 equity sharesConsideration vs TTM Revenue: ~207%Consideration vs Net Worth: ~20%
📅 Short termMarket may scrutinize cash outflow sources and the rationale for a micro-cap firm entering non-core distressed/corporate debt assignments.
📈 Long termOutcome hinges entirely on the recoverability of the ₹10.35 Cr debt or realization value from the 49% equity stake in Sparion Infrastructure.
⚠ Risk flags
- Acquisition is on an 'as is where is' and 'without recourse' basis, transferring all default risk to the company
- Promoter holding is extremely low (0.03%), increasing governance vigilance
- Substantial capital allocation relative to TTM revenue (207%) into non-core lending/debt recovery
Key Highlights
Assignment consideration stands at ₹10,35,35,520/-
Debt is acquired from Assignor M/s. Kshitij Polyline Limited owed by Sparion Infrastructure Private Limited
Underlying security includes pledge of 4,900 equity shares representing 49% equity shareholding of Sparion Infrastructure Private Limited
Assignment terms are on an 'as is where is', 'as is what is', and 'without recourse' basis
👀 What to Watch
Monitor how the company funds the ₹10.35 Cr payment and track subsequent disclosures regarding debt recovery or potential invocation of the 49% pledged equity stake.
Deep Health AI to acquire ₹10.35 Cr debt of Sparion Infrastructure from Kshitij Polyline
Deep Health AI India Ltd's Board approved the acquisition of debt owed by Sparion Infrastructure Private Limited from Kshitij Polyline Limited for ₹10.35 Cr. The transaction will be executed via a Deed of Assignment on an 'as is where is' and 'without recourse' basis. The acquisition includes underlying security, specifically a pledge of 4,900 equity shares (49% stake) of Sparion Infrastructure. Relative to Deep Health AI's TTM revenue of ₹5 Cr and net worth of ₹52 Cr, this assignment represents a significant capital commitment of over 200% of annual revenue.
Confidence: HIGH
What changedDeep Health AI agreed to acquire ₹10.35 Cr worth of third-party corporate debt along with a 49% share pledge as security.
Why it mattersThe deal size of ₹10.35 Cr is massive compared to the company's TTM revenue of ₹5 Cr and market cap of ₹28 Cr, exposing the balance sheet to recovery risk on an unrated borrower.
Assignment consideration: ₹10,35,35,520/-Pledged stake in borrower: 49%Pledged shares count: 4,900 equity sharesConsideration vs TTM Revenue: ~207%Consideration vs Net Worth: ~20%
📅 Short termMarket may scrutinize cash outflow sources and the rationale for a micro-cap firm entering non-core distressed/corporate debt assignments.
📈 Long termOutcome hinges entirely on the recoverability of the ₹10.35 Cr debt or realization value from the 49% equity stake in Sparion Infrastructure.
⚠ Risk flags
- Acquisition is on an 'as is where is' and 'without recourse' basis, transferring all default risk to the company
- Promoter holding is extremely low (0.03%), increasing governance vigilance
- Substantial capital allocation relative to TTM revenue (207%) into non-core lending/debt recovery
Key Highlights
Assignment consideration stands at ₹10,35,35,520/-
Debt is acquired from Assignor M/s. Kshitij Polyline Limited owed by Sparion Infrastructure Private Limited
Underlying security includes pledge of 4,900 equity shares representing 49% equity shareholding of Sparion Infrastructure Private Limited
Assignment terms are on an 'as is where is', 'as is what is', and 'without recourse' basis
👀 What to Watch
Monitor how the company funds the ₹10.35 Cr payment and track subsequent disclosures regarding debt recovery or potential invocation of the 49% pledged equity stake.
Deep Health AI to acquire ₹10.35 Cr debt of Sparion Infrastructure from Kshitij Polyline
Deep Health AI India Ltd's Board approved the acquisition of debt owed by Sparion Infrastructure Private Limited from Kshitij Polyline Limited for ₹10.35 Cr. The transaction will be executed via a Deed of Assignment on an 'as is where is' and 'without recourse' basis. The acquisition includes underlying security, specifically a pledge of 4,900 equity shares (49% stake) of Sparion Infrastructure. Relative to Deep Health AI's TTM revenue of ₹5 Cr and net worth of ₹52 Cr, this assignment represents a significant capital commitment of over 200% of annual revenue.
Confidence: HIGH
What changedDeep Health AI agreed to acquire ₹10.35 Cr worth of third-party corporate debt along with a 49% share pledge as security.
Why it mattersThe deal size of ₹10.35 Cr is massive compared to the company's TTM revenue of ₹5 Cr and market cap of ₹28 Cr, exposing the balance sheet to recovery risk on an unrated borrower.
Assignment consideration: ₹10,35,35,520/-Pledged stake in borrower: 49%Pledged shares count: 4,900 equity sharesConsideration vs TTM Revenue: ~207%Consideration vs Net Worth: ~20%
📅 Short termMarket may scrutinize cash outflow sources and the rationale for a micro-cap firm entering non-core distressed/corporate debt assignments.
📈 Long termOutcome hinges entirely on the recoverability of the ₹10.35 Cr debt or realization value from the 49% equity stake in Sparion Infrastructure.
⚠ Risk flags
- Acquisition is on an 'as is where is' and 'without recourse' basis, transferring all default risk to the company
- Promoter holding is extremely low (0.03%), increasing governance vigilance
- Substantial capital allocation relative to TTM revenue (207%) into non-core lending/debt recovery
Key Highlights
Assignment consideration stands at ₹10,35,35,520/-
Debt is acquired from Assignor M/s. Kshitij Polyline Limited owed by Sparion Infrastructure Private Limited
Underlying security includes pledge of 4,900 equity shares representing 49% equity shareholding of Sparion Infrastructure Private Limited
Assignment terms are on an 'as is where is', 'as is what is', and 'without recourse' basis
👀 What to Watch
Monitor how the company funds the ₹10.35 Cr payment and track subsequent disclosures regarding debt recovery or potential invocation of the 49% pledged equity stake.
Rs 1.9 Cr Net Loss in Q1 FY27 as Deep Health AI Shifts to Pharma Segment
Deep Health AI India reported a standalone net loss of Rs 1.90 crore for the quarter ended June 30, 2026, a sharp decline from a profit of Rs 0.09 crore in the year-ago period. While revenue from operations grew 200% YoY to Rs 45 lakhs, it was entirely driven by the pharmaceutical segment as the jewellery business reported zero revenue. The bottom line was weighed down by a significant spike in 'Other Expenses' totaling Rs 2.46 crore, which exceeded total income by over 4x. Despite the operational loss, a high Other Comprehensive Income of Rs 6.89 crore led to a Total Comprehensive Income of Rs 4.99 crore.
Confidence: HIGH
What changedThe company has effectively pivoted its revenue generation to the pharmaceutical segment, leaving its traditional jewellery business with zero revenue this quarter.
Why it mattersThe shift in business model is currently resulting in high operational costs and losses, which is critical for a micro-cap company with a market cap of only Rs 25 crore.
Revenue from Operations (Q1): Rs 45.00 lakhsNet Loss (Q1): Rs 189.90 lakhsOther Expenses: Rs 245.88 lakhsPharma Revenue Contribution: 100%Other Comprehensive Income: Rs 689.02 lakhsQ1 Revenue vs TTM Revenue: ~11.25%
📅 Short termThe significant operational loss and high expense ratio are likely to weigh on the stock price in the near term, despite the positive total comprehensive income figure.
📈 Long termThe long-term outlook depends on the company's ability to stabilize its new pharmaceutical business and achieve operational profitability after this transition phase.
⚠ Risk flags
- High unexplained other expenses
- Complete cessation of revenue from the original jewellery segment
- Extremely low promoter holding (0.03%)
Key Highlights
Revenue from operations increased to Rs 45.00 lakhs from Rs 15.00 lakhs in the same quarter last year.
Net loss for the quarter stood at Rs 189.90 lakhs compared to a profit of Rs 9.33 lakhs YoY.
Other expenses surged to Rs 245.88 lakhs, significantly impacting the operating margins.
Pharmaceutical segment contributed 100% of the Rs 45.00 lakhs revenue from operations, with zero revenue from Jewellery.
Total Comprehensive Income reached Rs 499.12 lakhs, bolstered by a Rs 689.02 lakh gain in Other Comprehensive Income.
👀 What to Watch
Investors should monitor the nature of the 'Other Expenses' and whether the pharmaceutical segment can scale sufficiently to cover these costs. The transition away from the jewellery business appears complete, making the company's healthcare/pharma execution the primary driver to watch.
Deep Health AI Reports Q1 FY27 Net Loss of ₹1.90 Cr; Pharma Revenue Grows 200% YoY
Deep Health AI India Ltd (formerly Deep Diamond India) reported a standalone net loss of ₹1.90 crore for Q1 FY27, a sharp decline from a profit of ₹0.09 crore in Q1 FY26. While revenue from operations grew 200% YoY to ₹45 lakhs, it was entirely offset by a surge in 'Other Expenses' which reached ₹2.46 crore. The company has effectively pivoted to the Pharmaceutical segment, which contributed 100% of operational revenue, while the legacy Jewellery business reported zero revenue. Despite the operational loss, a significant Other Comprehensive Income (OCI) of ₹6.89 crore led to a Total Comprehensive Income of ₹4.99 crore.
Confidence: HIGH
What changedThe company transitioned its revenue mix entirely to Pharmaceuticals in Q1 FY27 but suffered a significant operational loss due to a massive spike in expenses.
Why it mattersThe operational loss of ₹1.90 crore is substantial for a company with a ₹25 crore market cap and only ₹4 crore in TTM revenue, indicating high execution risk in its new business direction.
Q1 Revenue from Operations: ₹45.00 LakhsQ1 Net Loss: ₹1.90 CrOther Expenses: ₹2.46 CrQ1 Revenue vs TTM Revenue: 11.25%Promoter Holding: 0.03%
📅 Short termThe stock may face downward pressure as the market reacts to the operational loss and the high expense ratio, despite the accounting-driven total comprehensive profit.
📈 Long termThe company's pivot to Pharma and AI needs to demonstrate consistent revenue scaling and cost management to be viable; the lack of promoter skin in the game remains a structural concern.
⚠ Risk flags
- Extremely low promoter holding (0.03%)
- High 'Other Expenses' exceeding total revenue
- Operational loss at the segment level
- Reliance on OCI for positive total comprehensive income
Key Highlights
Revenue from operations increased to ₹45.00 lakhs in Q1 FY27 from ₹15.00 lakhs in Q1 FY26.
Net loss for the quarter stood at ₹189.90 lakhs compared to a profit of ₹9.33 lakhs in the same period last year.
Other expenses spiked to ₹245.88 lakhs, representing 546% of the quarter's revenue from operations.
Pharmaceutical segment revenue grew to ₹45.00 lakhs, while the Jewellery segment recorded ₹0 revenue.
Total Comprehensive Income reached ₹499.12 lakhs, primarily driven by ₹689.02 lakhs in Other Comprehensive Income.
👀 What to Watch
Monitor the nature of the 'Other Expenses' which caused the significant operational loss and track the sustainability of the Pharmaceutical segment's growth. Investors should remain cautious due to the extremely low promoter holding of 0.03% and the reliance on non-operational income (OCI) for the positive bottom line.
Rs 2.85 Cr Advance Paid for 49,100 Sq Mtr Land Acquisition for Wellness Pivot
Deep Health AI India Ltd (formerly Deep Diamond India Ltd) has disclosed a delayed update regarding the acquisition of 49,100 sq. mtr. of land in Pune, Maharashtra. The company has paid an aggregate advance of Rs 2.85 crore in 10 tranches to Elegant Floriculture & Agrotech (India) Limited, with the final payment made on June 06, 2026. This acquisition marks a strategic shift toward wellness and agro-tourism, including a naturopathy centre and medicinal plant cultivation. The disclosure was delayed by over four months from the initial MoU date of March 06, 2026, which the company attributed to an administrative oversight.
Confidence: MEDIUM
What changedThe company has committed Rs 2.85 Cr to a new business vertical (wellness/agro-tourism) and admitted to a regulatory disclosure delay regarding the land acquisition.
Why it mattersThis represents a significant pivot from the company's legacy Gems and Jewellery background into healthcare and wellness, requiring entirely different operational expertise and capital allocation.
Advance Payment: Rs 2,85,00,000Land Area: 49,100 sq. mtr.MoU Date: March 06, 2026Last Tranche Date: June 06, 2026
📅 Short termThe stock may see volatility as the market processes the cash outflow and the governance lapse regarding the delayed disclosure.
📈 Long termThe long-term success depends on the company's ability to execute in the wellness and agro-tourism sector, which is a complete departure from its original industry; the pivot is high-risk.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Delayed regulatory disclosure
- Business model pivot risk
- Execution risk in a new industry
- Significant downward price trend (-62.3% in 6 months)
Key Highlights
Advance payment of Rs 2,85,00,000 (Rs 2.85 Cr) made for land acquisition
Land area totals 49,100 sq. mtr. located in Maval, Pune, Maharashtra
MoU signed on March 06, 2026, with the final advance tranche paid on June 06, 2026
Project focus includes a naturopathy centre and cultivation of medicinal plant species
Disclosure made on July 13, 2026, following a delay from the original March 2026 MoU date
👀 What to Watch
Monitor the timeline for the final sale deed and the commencement of the naturopathy project. Investors should also watch for any regulatory penalties or queries regarding the delayed disclosure of this material transaction.
